Materials and Methods
Following receipt of approval from the local ethical committee (No. 2017-05/04), this prospective study was performed with patients aged 65 and over presenting to the Kirikkale University Medical Faculty Hospital ED between 01 January and 30 July, 2017, and using multi-drugs for at least one year. Signed informed consent forms were obtained from patients and/or relatives to confirm that they were participating on a voluntary basis. The study was performed in accordance with the Declaration of Helsinki and the Good Clinical Practice Directive.
Patients' age, sex, alcohol use or smoking status, herbal medication use, medications used, comorbid diseases ED presentation symptoms and frequency of presentations were recorded. Relations between DDCs, drug-drug interactions and side-effects and presentation symptoms were checked using Beers criteria and the 'drug interactions checker' from the Medscape web site (9, 10) .
Subjects who refused to participate, patients aged under 65, using less than two medications, taking drugs for purposes of suicide, patients with whom clear communication could not be established (with clouded consciousness, impaired cognitive functions, or with speech or hearing disabilities) and trauma patients were excluded.
Statistical Analysis
All data were analyzed on SPSS 23.0 (Statistical Package for the Social Sciences Inc., Chicago, IL, USA) software. Normality of distribution was assessed using the Shapiro-Wilks test. Quantitative data were expressed as median and interquartile range (IQR), and qualitative data as number (n) and frequency (%). Non-parametric data were analyzed using the Mann-Whitney U test and the Kruskal-Wallis test, while categorical data were analyzed using the Chi-square and Fisher Exact tests. Spearman's rho correlation test was used to compare quantitative data. p values <0.05 were regarded as statistically significant.
Results
During the study period, 3313 patients aged 65 or over presented to the ED. Of these, 1029 were excluded because of presenting due to trauma, 1302 due to absence of polypharmacy, 563 because clear communication could not be established, and 119 due to declining to take part in the study, which was eventually completed with 300 patients.
The mean age of the patients was 72.2 ± 6.7 years (range: 65-91), and 54% (n=162) were women. DDCs was determined in 94.6% (n=284) of patients, and 24.3% (n=73) of presentation symptoms were associated with drug interactions. Women constituted 55.3% of the subjects with DDCs and 50.7% of those with presentation symptoms associated with drug interactions. No statistically significant relation was observed between gender and DDCs or presentation symptoms being associated with drug interactions (p=0.061; 0.514, respectively).
The mean age of the patients with DDCs was 72.4 ± 6.7 years, compared to 68.3 ± 5.5 in subjects without DDCs (p=0.016). The mean age of subjects with presentation symptoms associated with drug interactions was 71.2 ± 5.7, compared to 72.5 ± 7.0 in those whose symptoms were not associated with drug interactions (p=0.156) ( Table 1) .
Mean numbers of medications used per day were 6.8 ± 2.5 in patients with DDCs and 5.5 ± 1.4 in without DDCs (p=0.04). Mean numbers of medications used per day by patients with presentation symptoms associated with drug interactions were 6.7 ± 2.5, compared to 7.0 ± 2.2 in the other patients (p=0.086). Mean numbers of presentations to the ED were 8.3 ± 6.3 /year in patients with DDCs and 1.9 ± 0.4 /year in without DDCs (p<0.001). Mean numbers of presentations to the ED were 9.4 ± 7.1 /year in patients with presentation symptoms associated with drug interactions and 7.1 ± 6.1 /year in the other patients (p=0.045) ( Table  1 ). Positive correlation was determined between frequency of presentations to the EDs among elderly and numbers of medications used (r: 0.514; p<0.001).
Eighteen different drug groups, 192 different pharmacological contents, and 2011 different medications were used. The three most common drug groups were antiarrhythmics (15.4%), antithrombotics and anticoagulants (13.1%) and antihypertensives (10.2%), and the three most commonly used medications were aspirin (6.5%), metoprolol (4.7%) and furosemide (4.7%) ( Table  2 ). The only relation was determined between subjects with DDCs and anti-hypertensive group drugs (p<0.001); no relation was determined between presentation symptoms associated with drug interactions and any drug group (Table 3) .
We observed 438 different DDCs in our patients. The most common of these were 'aspirin + anticoagulant' (10.7%), 'aspirin + metoprolol' (9.8%) and 'aspirin + ACE inhibitors' (8.7%) combinations. The most common sideeffect resulting from drug interactions in these combinations was 'bleeding' (including gastrointestinal bleeding, intracranial hemorrhage, epistaxis, hematuria, alveolar haemorrhage), which was most prevalent in the "aspirin + anticoagulant" combinations. The next most common side-effect was dyspnea, most prevalent in the 'metoprolol + bronchodilators' combination ( Table 4 ).
The three most common comorbid diseases in elderly patients were hypertension (HT) in 76.1%, diabetes mellitus (DM) in 54.3%, and coronary artery disease at 37.3%. No relation was determined between DDC and comorbid diseases, although a correlation was observed between presentation symptoms and CAD ( Table 5 ).
The three most common symptoms on presentation to the ED were dyspnea (27.7%), chest pain (20.3%), and headache and/or dizziness (13.3%). While no relation was determined between DDCs and presentation symptoms, correlations were observed between dyspnea and bleeding, and drug interaction (p<0.001; <0.001, respectively) ( Table  6 ).
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Examination of the medications used by elderly patients based on Beers criteria revealed that;
• Medications always to be avoided were used at a level of 38.9%,
• Medications to be avoided in elderly patients with certain diseases and syndromes were used at a level of 13.4%,
• Medications to be used with caution in elderly patients were used at a level of 29.4%. 
Discussion
The prevalence of drug-drug interactions and side-effects is growing because of an increase due to aging in the prevalence of chronic diseases (and thus in the numbers of medication used), the use of herbal therapies, the use of prescribed or over-the-counter medicines, and changes induced by dose repetitions resulting from forgetfulness and in drug metabolism (11, 12) . This is related to gender, as well as aging. Studies have shown that since women have longer life expectancies than men, they are also exposed to more chronic disease, and thus to more drug interactions or DDCs development (13, 14) . Topbaş et al. reported mean ages of 69.9 years for women and 70.5 for men in elderly patients regularly using medications (15) , while Arslan et al. reported mean ages of 77.1 for women and 74.3 for men (16) . The mean age of the patients in our study was 72.2, and the majorities were women. Mean age was higher in patients with DDCs than in those without DDCs, and the difference was statistically significant. However, although the number of women was higher among the subjects with DDCs, we determined no correlation between DDC and gender. Although these findings are similar to those of previous studies, DDC development was associated only with increased age, and was independent of gender.
Chronic and/or comorbid diseases are common among elderly individuals (6, 17) . Ünsal et al. reported the presence of at least one chronic disease in 82% of elderly patients, the most common being HT, DM and COPD (18) . Chiovanda et al. reported a different sequence, in the form of pulmonary system diseases, DM and cardiovascular system diseases (19) . Although the sequences vary from study to study, the risk of polypharmacy and associated drug-drug interaction or DDCs due to the presence of chronic diseases or new diseases persists.
Studies on this subject have reported that simultaneous use of anticholinergic drugs, the use of antidiabetic drugs with alcohol, steroids, antihypertensive or antipsychotics, the use of antibacterial medications with mono-amino oxidase inhibitors, and the use of diuretics with antihypertensive all lead to severe drug interactions and DDCs development (20, 21) . The most common diseases in our study were HT, diabetes mellitus, and CAD. Moreover, in addition to newly developing infections, musculoskeletal system disorders were also present in some patients. This all indicated that numerous drugs to be used for both new and old diseases will result in new interactions, side-effects and DDCs. However, we determined no correlation between comorbid diseases and DDCs development. Presentation symptoms associated with drug interactions were only correlated with CAD. This may be due to medications from several groups (antiarrhythmic, antihypertensive, diuretic, antithrombotic, anticoagulant, etc.) being used together in CAD. We attributed the lack of any relation between comorbid diseases and DDCs to the absence of combinations that might result in a statistically significant finding due to medications that might cause DDCs being distributed to different patients.
Since multidrug use in elderly patients can give rise to new side-effects, this can suppress the symptoms and findings of existing diseases. Emerging side-effects may also constitute a primary cause of presentation symptoms (22, 23) . Cahir et al. reported the most common side effects resulting in presentations to hospital due to drug interactions in elderly patients as bleeding, dyspepsia, dizziness and impairment of the decision-making mechanism. They attributed the emergence of these to warfarin, aspirin, NSAID and psychotropic drugs, respectively (24) . Banerjee at al. The most frequent presentation symptom in our study was dyspnea, and a correlation was determined with drug interaction. Dyspnea is associated with several acute (seasonal conditions and respiratory tract infections) or chronic (COPD, bronchitis, pulmonary embolism, heart failure, kidney failure, etc.) diseases. At the same time, it may also emerge in association with the use of bronchodilator medications and β-blockers, with cardiac dysfunction, or with other drug combinations that reduce the effectiveness of diuretics.
The medications that most commonly cause drug interactions in elderly patients are anticoagulants, NSAIDs, antihypertensives, antiarrhythmics, antidiabetics, diuretics and antibiotics (6, 21, 26) . Warfarin is the best known oral anticoagulant and interacts with several medications (27) . In addition to reducing the effect of diuretics and βblockers, NSAIDs also adversely affect gastrointestinal system (GIS) and renal blood supply, but are commonly used in all age groups, not only by the elderly (28) . Sari et al. investigated the relation between GIS bleeding and medication use in elderly patients and determined an association with NSAID, aspirin and warfarin use (29) . In our study, both aspirin and NSAIDs were frequently used by elderly patients. The most commonly employed combinations were 'aspirin + metoprolol', 'aspirin + furosemide' and 'aspirin + anticoagulant'. In addition, we determined that antithrombotics, anticoagulants, antiarrhythmics, antihypertensives, diuretics, and angiotensin receptor blockers were frequently used together during the treatment of inter-related diseases such as CAD and HT. Although this is essential for the routine treatment of various diseases, it also leads to bleeding associated with drug-drug interactions. Another finding was that the incidence of DDCs was significantly higher in patients using anti-hypertensive medications. We attribute this to monotherapy being insufficient in the treatment of HT, to patients using numerous and various anti-hypertensive medications on the market together under different names (although their contents are the same), or to the addition of further drugs to treat secondary organ damage occurring due to HT.
The number of daily medications used is another cause of interaction-related effects. Studies have reported 2-9 medications a day being used in elderly patients (6, 30, 31) . Several studies have shown that an increase in the numbers of drugs used also raises the probability of drug interactions, DDCs and side-effects (11, 12, 32) . Field et al. reported that the risk of adverse reactions in multidrug use increased to 13% in patients using two medications, to 58% in those using five, and to 82% in those using seven or more (32) . Bjorkman et al. reported a positive correlation between the probability of drug-drug interaction and numbers of medications used (33) . In contrast, Pozzi et al. reported that an increase in hospital presentations associated with drug interactions was correlated, not with the numbers of medications used, but with the combined used of potentially inappropriate medications (34) . In our study, the prevalence of DDCs increased in subjects using larger daily numbers of medications. Numbers of presentations to hospital were also significantly high in these patients. A higher number of medications facilitates potential side-effects, drug-drug interactions, the emergence of DDCs and an increased number of ED presentations. We think that although more DDCs emerged in patients using higher numbers of medications, numbers of presentations to the ED were not solely associated with the mean number of medications used, and that various combinations may result in hazardous interactions irrespective of medication numbers.
Studies have reported that elderly people constitute 9-23% of patients presenting to the ED, and that polypharmacy causing drug interactions in these patients increases both outpatient treatment and hospitalization (35, 36) . Numbers of medications used in elderly individuals are related to drug interactions and numbers of presentations to hospital (37, 38) . Sehgal et al. showed a positive correlation between multidrug use and DDCs and numbers of presentations to hospital (39) . The level of patients presenting to the ED due to drug interactions in the present study was 24.3%. This was statistically significantly higher than the level in patients presenting with both DDCs and drug interaction. In addition, we also determined positive correlation between numbers of presentations and numbers of medications used. These findings are in agreement with previous studies reporting that increased numbers of medications used in elderly patients also increase DDCand drug interaction-related hospital presentations.
Conclusion
Numbers of medications used and DDCs increase with age in elderly. This particularly applies to subjects with CAD, and using antihypertensive drugs. An increase in the number of medications used results in an increase in drug interactions and hospital presentations, the main presentation symptoms being dyspnea and bleeding. Under these conditions, dyspnea is generally caused by combined use of bronchodilators and β-blockers, while bleeding is generally caused by combined aspirin and warfarin. Further, wide-ranging studies regarding rational medication use and patient safety in the elderly are now needed.Limitations: The most important limitations of our study were the absence of control group and low number of patients. The other limitations are as follows: Long-term follow-ups of the patients were not performed and evaluation about the other subjects, except pain scale was not made.
